Wave Life Sciences Ltd (NASDAQ:WVE) – Investment analysts at SunTrust Banks boosted their Q1 2018 earnings per share estimates for Wave Life Sciences in a research note issued on Monday, March 12th, according to Zacks Investment Research. SunTrust Banks analyst E. Nash now anticipates that the company will earn ($0.88) per share for the quarter, up from their previous estimate of ($0.98). SunTrust Banks has a “Buy” rating and a $60.00 price target on the stock. SunTrust Banks also issued estimates for Wave Life Sciences’ Q2 2018 earnings at ($0.90) EPS, Q3 2018 earnings at ($0.83) EPS, Q4 2018 earnings at ($0.85) EPS, FY2019 earnings at ($2.84) EPS, FY2020 earnings at ($3.04) EPS, FY2021 earnings at $1.46 EPS and FY2022 earnings at $5.66 EPS.
Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings results on Monday, March 12th. The company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.00) by ($0.09). The firm had revenue of $1.68 million for the quarter, compared to analysts’ expectations of $0.63 million. Wave Life Sciences had a negative net margin of 2,754.73% and a negative return on equity of 66.73%.
Several other brokerages have also recently weighed in on WVE. BidaskClub raised shares of Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 21st. Leerink Swann increased their price target on shares of Wave Life Sciences from $53.00 to $64.00 and gave the company an “outperform” rating in a research report on Wednesday, February 21st. Mizuho set a $34.00 price target on shares of Wave Life Sciences and gave the company a “buy” rating in a research report on Tuesday, February 20th. Zacks Investment Research cut shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. Finally, TheStreet raised shares of Wave Life Sciences from a “d+” rating to a “c-” rating in a research report on Friday, January 5th. Two analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Wave Life Sciences currently has an average rating of “Buy” and a consensus target price of $53.40.
WVE traded down $1.00 during trading on Thursday, hitting $39.80. 93,696 shares of the stock traded hands, compared to its average volume of 148,876. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.67 and a quick ratio of 7.67. Wave Life Sciences has a 12-month low of $15.15 and a 12-month high of $55.95.
Several institutional investors have recently modified their holdings of the stock. Bridger Management LLC increased its stake in shares of Wave Life Sciences by 16.2% in the 4th quarter. Bridger Management LLC now owns 337,949 shares of the company’s stock worth $11,862,000 after acquiring an additional 47,064 shares in the last quarter. Perceptive Advisors LLC increased its stake in Wave Life Sciences by 3.1% during the 4th quarter. Perceptive Advisors LLC now owns 662,798 shares of the company’s stock valued at $23,264,000 after purchasing an additional 20,000 shares in the last quarter. Two Sigma Investments LP bought a new stake in Wave Life Sciences during the 4th quarter valued at about $828,000. Goldman Sachs Group Inc. bought a new stake in Wave Life Sciences during the 4th quarter valued at about $222,000. Finally, Spark Investment Management LLC bought a new stake in Wave Life Sciences during the 4th quarter valued at about $1,411,000. Institutional investors own 79.40% of the company’s stock.
In related news, insider Chris Francis sold 21,639 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $55.40, for a total value of $1,198,800.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Chandra Vargeese sold 2,000 shares of the stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $40.00, for a total transaction of $80,000.00. The disclosure for this sale can be found here. Insiders sold a total of 24,466 shares of company stock valued at $1,321,808 over the last 90 days. Company insiders own 53.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/wave-life-sciences-ltd-to-post-q1-2018-earnings-of-0-88-per-share-suntrust-banks-forecasts-wve.html.
Wave Life Sciences Company Profile
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Get a free copy of the Zacks research report on Wave Life Sciences (WVE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.